How Much Does NMN/NR Cost in Maryland in 2026?

Maryland Retail Pharmacy Pricing for NMN and NR

The average cash-pay price for pharmaceutical-grade NMN across Maryland retail pharmacies sits at $80 per month in 2026. This figure reflects a once-daily oral capsule at standard doses of 250 mg to 500 mg. Prices vary by $15 to $30 depending on whether you fill at an independent pharmacy in Baltimore, a chain in Montgomery County, or a compounding-focused shop in Annapolis.

NR (nicotinamide riboside) pricing follows a similar band. Brand-name Niagen (the patented NR form from ChromaDex) runs $40 to $50 per month as an over-the-counter supplement, but prescription-grade formulations compounded to higher doses cost more. The distinction matters clinically: Yoshino et al. demonstrated in a 2021 randomized controlled trial (N=25) that NMN at 250 mg daily for 10 weeks improved skeletal muscle insulin sensitivity in prediabetic women, with insulin-stimulated glucose disposal increasing by 25% compared to placebo 1. That study used pharmaceutical-grade NMN, not supplement-tier product.

Maryland has no state-level price caps on compounded medications or NAD precursors specifically. Pricing is set by individual pharmacies. The Maryland Board of Pharmacy regulates compounding standards but does not intervene on pricing 2.

For patients paying out of pocket, the total monthly cost including a telehealth consultation fee ($50 to $99 for the initial visit, $30 to $50 for follow-ups) lands between $110 and $180 in the first month, dropping to $80 to $130 for subsequent refills.

Compounded Nicotinamide Mononucleotide: Maryland 503A Access

Compounded NMN is legal in Maryland through licensed 503A pharmacies. These pharmacies operate under individual patient prescriptions and must comply with both federal Section 503A requirements and Maryland Board of Pharmacy regulations. A valid prescription from a licensed provider is required.

503A compounding pharmacies in Maryland can formulate NMN as oral capsules, sublingual tablets, or injectable preparations. Sublingual formulations bypass first-pass hepatic metabolism and may achieve higher NAD+ bioavailability, though head-to-head pharmacokinetic data in humans remains limited. A 2022 pharmacokinetic study showed that oral NMN at 300 mg raised whole-blood NAD+ levels by approximately 40% over baseline at 60 days 3.

Compounded NMN pricing in Maryland breaks down roughly as follows:

• 250 mg oral capsule, 30 count: $40 to $60
• 500 mg oral capsule, 30 count: $65 to $95
• Sublingual tablet, 250 mg, 30 count: $70 to $120
• Injectable NAD+ (compounded, not NMN per se): $150 to $400 per infusion

Maryland does not restrict which compounding pharmacies can ship within state lines. Patients in rural areas of Western Maryland or the Eastern Shore can receive compounded NMN by mail from any Maryland-licensed 503A pharmacy.

Maryland Medicaid Coverage for NMN/NR

Maryland Medicaid covers NMN/NR with prior authorization. This is not automatic. The prescribing provider must submit clinical documentation establishing medical necessity, which typically requires evidence of a diagnosed condition for which NAD+ repletion has documented benefit.

Prior authorization criteria in Maryland generally require:

• A documented diagnosis (examples: metabolic syndrome, age-related NAD+ depletion confirmed by blood NAD+ assay, or as adjunctive therapy for conditions with mitochondrial dysfunction)
• Failure of or contraindication to first-line interventions
• Prescriber attestation of expected clinical benefit

Approval rates for NAD precursors under Maryland Medicaid are not publicly reported, but clinical pharmacists familiar with the process note that applications linked to metabolic endpoints (insulin resistance, documented NAD+ deficiency) receive approval more frequently than those citing general "longevity" or "anti-aging" goals.

The 2020 Endocrine Society Scientific Statement on NAD+ metabolism acknowledged that "NAD+ decline is a hallmark of aging and contributes to the pathophysiology of multiple age-related diseases," though it stopped short of recommending supplementation as standard of care 4. Maryland Medicaid reviewers reference such guideline-level statements when adjudicating prior authorization requests.

Processing time for prior authorization averages 5 to 10 business days. Expedited review is available when the prescriber documents urgent medical need.

Commercial Insurance Coverage in Maryland

Most commercial insurance plans in Maryland do not cover NMN or NR. CareFirst BlueCross BlueShield, the dominant insurer in the state, classifies NAD precursors as "investigational" for most indications. Kaiser Permanente Mid-Atlantic and Aetna plans available through Maryland Health Connection similarly exclude coverage.

There are narrow exceptions. Some employer-sponsored plans with longevity medicine riders or executive health benefits may reimburse compounded NMN as part of a broader metabolic optimization protocol. These plans are uncommon and concentrated among technology firms and federal contractors headquartered in the Baltimore-Washington corridor.

Patients with HSA (Health Savings Account) or FSA (Flexible Spending Account) funds can use these pre-tax dollars for prescription NMN if they have a valid prescription and a Letter of Medical Necessity from their provider. The IRS requires that the expense treat a specific medical condition, not general wellness 5.

A practical workaround: some Maryland patients obtain a prescription for NMN alongside documented lab work showing low NAD+ levels or elevated inflammatory markers, then submit for reimbursement through their FSA/HSA administrator. Acceptance rates vary by plan administrator.

Telehealth Prescribing of NMN/NR in Maryland

Telehealth prescribing of NMN and NR is legal in Maryland. The Maryland Board of Physicians allows providers to establish a patient-provider relationship via synchronous audio-video telehealth and prescribe medications including compounded formulations without an in-person visit.

Maryland telehealth regulations (COMAR 10.32.05) require that the provider be licensed in Maryland or hold a valid telehealth registration. Out-of-state providers using the Interstate Medical Licensure Compact can also prescribe to Maryland residents if they hold a compact license.

Typical telehealth consultation costs for NMN/NR prescribing in Maryland:

• Initial consultation: $50 to $150 (includes medical history review, lab order)
• Follow-up visits: $30 to $75 (every 60 to 90 days)
• Lab work (NAD+ levels, metabolic panel): $100 to $250 out of pocket, or covered by insurance as routine bloodwork

The total first-year cost for a Maryland patient using telehealth to access prescription NMN at 500 mg daily, including four consultations and monthly compounded capsules, ranges from $1,100 to $1,800. That breaks down to roughly $92 to $150 per month all-in.

How to Reduce NMN/NR Costs in Maryland

Several strategies can lower the effective monthly cost for Maryland residents.

Compounding pharmacy price comparison. Maryland has over 60 licensed compounding pharmacies. Prices for the same 500 mg NMN capsule formulation can differ by 40% between pharmacies in the same metro area. Calling three pharmacies before filling saves an average of $15 to $25 per month.

90-day fills. Most compounding pharmacies offer a 10% to 15% discount for 90-day supply orders. On a $80/month regimen, that saves $96 to $144 annually.

Manufacturer programs. Some NR supplement manufacturers (ChromaDex for Niagen, Elysium for Basis) offer subscription discounts of 15% to 25% for auto-ship orders. These are OTC supplement products, not prescription-grade, but may be appropriate for patients whose providers recommend lower doses.

Combination formulations. Some 503A pharmacies compound NMN with trimethylglycine (TMG) or resveratrol in a single capsule, reducing the per-ingredient cost compared to purchasing each separately. A combination capsule containing 250 mg NMN plus 500 mg TMG typically costs $5 to $10 less per month than buying both separately.

University-affiliated clinics. Johns Hopkins and University of Maryland Medical System both have integrative medicine divisions where residents or fellows may see patients at reduced consultation fees ($30 to $50 for follow-ups), lowering the non-drug cost component.

Dr. David Sinclair of Harvard Medical School has stated: "NMN is one of the most promising NAD+ precursors for reversing aspects of aging at the cellular level, but access and cost remain barriers for many patients" 6.

NMN vs. NR: Cost Comparison in Maryland

NMN and NR both raise NAD+ levels, but they differ in price, regulatory status, and bioavailability data.

NR (as Niagen) holds New Dietary Ingredient (NDI) status with the FDA and is widely sold over the counter. Pricing for OTC NR in Maryland: $40 to $55 per month for 300 mg daily. Prescription compounded NR at higher doses: $60 to $90 per month.

NMN occupies a more complex regulatory position. The FDA issued a letter in 2022 questioning whether NMN qualifies as a dietary supplement, given that it was under investigation as a drug (by Metro International Biotech). This created uncertainty. Some supplement companies continued selling NMN OTC; others pivoted to prescription-only compounded formulations.

In Maryland, compounded NMN remains available by prescription through 503A pharmacies regardless of the FDA's supplement classification determination, because compounding regulations operate under a separate legal framework (FDCA Section 503A).

A 2023 meta-analysis of six RCTs (total N=196 participants) found that both NMN and NR supplementation significantly increased blood NAD+ levels compared to placebo, with a pooled standardized mean difference of 0.80 (95% CI: 0.47 to 1.13, P<0.001) 7. The analysis did not find a statistically significant difference between NMN and NR in NAD+ elevation, though direct head-to-head trials are lacking.

For Maryland patients choosing on cost alone: OTC NR is cheaper. For those who want higher doses or sublingual/injectable formulations, compounded NMN through a 503A pharmacy offers more flexibility but at a higher price point.

Maryland-Specific Regulatory Considerations

The Maryland Board of Pharmacy updated compounding regulations in 2024, aligning more closely with USP <795> and USP <797> standards. These changes affect how 503A pharmacies prepare NMN formulations but did not restrict patient access.

Key regulatory facts for Maryland NMN access:

• No state-level ban or restriction on NMN compounding
• 503A pharmacies must compound pursuant to a valid, patient-specific prescription
• 503B outsourcing facilities can supply NMN to healthcare facilities without patient-specific prescriptions
• Maryland does not require a specific diagnosis code for NMN prescriptions (unlike some states that restrict compounding to FDA-approved indications)
• The Maryland Pharmacy Act does not classify NMN as a controlled substance

The Endocrine Society's 2023 position paper noted: "NAD+ precursors including NMN and NR show promise in early clinical trials for metabolic health, but long-term safety data beyond 12 months in humans are still needed before broad clinical adoption can be recommended" 8.

Maryland providers prescribing NMN are expected to document clinical rationale and monitor patients with periodic lab work (NAD+ levels, liver function, metabolic panels) per standard practice for off-label prescribing.

What Lab Work Should Maryland Patients Expect?

Before initiating NMN/NR therapy, most Maryland providers order baseline labs. After starting therapy, repeat labs at 60 to 90 days assess response.

Standard panel includes:

• Whole-blood NAD+ level (baseline and follow-up)
• Comprehensive metabolic panel (CMP)
• Fasting insulin and glucose
• Lipid panel
• Liver function tests (AST, ALT)
• Inflammatory markers (hs-CRP)

Lab costs in Maryland for this panel: $150 to $300 out of pocket at direct-pay labs (Quest, Labcorp), or covered under preventive care benefits if ordered alongside routine bloodwork. Some telehealth platforms include lab orders in their consultation fee.

A 2022 dose-escalation study (N=80) found that NMN at doses up to 1 to 200 mg daily for 60 days produced no clinically significant adverse changes in liver enzymes, renal function, or hematologic parameters 9. Monitoring remains standard practice given the limited long-term human safety database.

Patients taking NMN at 500 mg daily can expect whole-blood NAD+ to increase by 30% to 50% over baseline within 30 to 60 days, based on available pharmacokinetic data.